U.S. markets close in 5 hours 51 minutes

Minerva Neurosciences, Inc. (NERV)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
3.2800-0.0400 (-1.20%)
As of 10:06AM EST. Market open.

Minerva Neurosciences, Inc.

1601 Trapelo Road
Suite 286
Waltham, MA 02451
United States
617 600 7373

Full Time Employees9

Key Executives

NameTitlePayExercisedYear Born
Dr. Remy Luthringer Ph.D.Exec. Chairman & CEO1.19MN/A1961
Mr. Geoffrey Robin Race F.C.M.A., FCMA, M.B.A., MBAPres880.44kN/A1961
Mr. Frederick W. Ahlholm CPA, CPASr. VP, CFO & Sec.610.68kN/A1966
Prof. Michael Davidson M.D.Chief Medical Officer657.47kN/A1950
Mr. Joseph ReillySr. VP & COON/AN/A1975
Mr. William B. BoniVP of Investor Relations & Corp. CommunicationsN/AN/A1952
Dr. Ramana Kuchibhatla Ph.D.Sr. VP and Head of R&DN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for the treatment of schizophrenia; and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Corporate Governance

Minerva Neurosciences, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.